Partner with Shionogi
Increasing Patient Options Through Partnering
- The industry leading ViiV Joint Venture with GSK and Pfizer to treat HIV/AIDS patients
- A partnership with Duchesnay on Osphena® (ospemifene) in the US and Canada, a product developed by Shionogi for the treatment of dyspareunia
- An out-licensing deal with BioDelivery Sciences Inc. on Symproic® (naldemedine), a product developed by Shionogi for the treatment of opioid induced constipation for the US market
- Anti-viral collaboration with Roche in the US and Europe on Xofluza® (baloxavir marboxil), a single use therapy for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours
Therapeutic Areas of Interest
Infectious Diseases/Hospital Based Therapies
Shionogi established a meaningful hospital presence following the 2020 launch of our drug product Fetroja® (cefiderocol) for patients 18 years of age or older with complicated urinary tract infections (c-UTI), hospital-acquired pneumonia or ventilator-associated pneumonia (HAP/VAP) caused by susceptible Gram-negative microorganisms. We hope to partner with companies on assets that can utilize our experienced field-based Fetroja team to bring complementary products to patients in the hospital or possibly out-patient as well, if a particular asset can be used in both settings.
Central Nervous System (CNS)
As noted above, Shionogi has a long track record developing products in CNS, including products for depression, ADHD and pain. In 2020, Shionogi acquired Tetra Therapeutics, which has a leading development compound for the treatment of fragile X syndrome (BPN-14770). In that context, Shionogi is seeking products in many specialty CNS areas including, but not limited to autism, epilepsy, ALS, Parkinson’s associated conditions, and more. It is Shionogi’s intention to utilize these CNS product opportunities to assist in the creation of a stand-alone outpatient business unit, separate from our efforts in the hospital.
If you or your organization wish to connect with us to discuss an opportunity or to begin a dialogue, please contact Shionogi Business Development at Business.Development@Shionogi.com. A member of the Shionogi US Business Development team will review your correspondence and respond accordingly in an appropriate timeframe.
Thank you for your interest in partnering with Shionogi. We look forward to hearing from you and potentially working together to supply the best possible medicine to protect the health and wellbeing of the patients we serve.